NASDAQ:TVRD Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $1.15 -0.09 (-7.26%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.18 +0.03 (+2.17%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Tvardi Therapeutics Stock (NASDAQ:TVRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tvardi Therapeutics alerts:Sign Up Key Stats Today's Range$1.13▼$1.2850-Day Range$1.06▼$2.5452-Week Range$0.93▼$43.65Volume313,802 shsAverage Volume221,309 shsMarket Capitalization$15.34 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression. Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is also developing additional STAT3-targeted programs intended to expand its therapeutic pipeline and potentially address multiple oncology indications. Tvardi Therapeutics is headquartered in Houston, Texas, and conducts research and clinical development activities through collaborations with medical and research institutions. Its programs remain investigational and are subject to ongoing clinical evaluation for safety and effectiveness.AI Generated. May Contain Errors. Read More Tvardi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreTVRD MarketRank™: Tvardi Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 181st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTvardi Therapeutics has a consensus price target of $18.00, representing about 1,465.2% upside from its current price of $1.15.Amount of Analyst CoverageTvardi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tvardi Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.35) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tvardi Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tvardi Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTvardi Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.07% of the float of Tvardi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTvardi Therapeutics has a short interest ratio ("days to cover") of 2.29, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tvardi Therapeutics has recently decreased by 3.57%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTvardi Therapeutics does not currently pay a dividend.Dividend GrowthTvardi Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentTvardi Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tvardi Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for TVRD on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.40% of the stock of Tvardi Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tvardi Therapeutics' insider trading history. Receive TVRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVRD Stock News HeadlinesTvardi Therapeutics (NASDAQ:TVRD) & Phibro Animal Health (NASDAQ:PAHC) Financial ContrastOctober 1 at 6:46 AM | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Rating Lowered to "Strong Sell" at Wall Street ZenSeptember 26, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 3 at 1:00 AM | Chaikin Analytics (Ad)Tvardi pubblica dati preclinici su inibitore STAT3 per la coliteSeptember 25, 2026 | it.investing.comNew Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)September 25, 2026 | finance.yahoo.comTvardi Therapeutics, Inc. Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In Ulcerative ColitisSeptember 25, 2026 | marketscreener.comMNew Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)September 24, 2026 | globenewswire.comTvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 23, 2026 | americanbankingnews.comSee More Headlines TVRD Stock Analysis - Frequently Asked Questions How have TVRD shares performed this year? Tvardi Therapeutics' stock was trading at $4.30 on January 1st, 2026. Since then, TVRD shares have decreased by 73.3% and is now trading at $1.15. How were Tvardi Therapeutics' earnings last quarter? Tvardi Therapeutics, Inc. (NASDAQ:TVRD) released its quarterly earnings data on Friday, August, 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.04. When did Tvardi Therapeutics IPO? Tvardi Therapeutics (TVRD) raised $60 million in an initial public offering (IPO) on Friday, January 31st 2014. The company issued 5,000,000 shares at $11.00-$13.00 per share. How do I buy shares of Tvardi Therapeutics? Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 10 days, TVRD's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TVRD Previous SymbolNASDAQ:TVRD CIK1346830 Webwww.tvarditherapeutics.com Phone(713) 489-8654Fax203-567-1510Employees80Year Founded2004Price Target and Rating Average Price Target for Tvardi Therapeutics$18.00 High Price Target$61.00 Low Price Target$5.00 Potential Upside/Downside+1,465.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-145.40% Return on Assets-91.11% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.52Miscellaneous Outstanding Shares13,339,000Free Float12,352,000Market Cap$15.34 million OptionableN/A Beta0.38 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TVRD) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVRD Stock Alerts